Baku, March 11, AZERTAC
Pfizer announced Wednesday it is launching a clinical trial to study the effectiveness of its COVID-19 antiviral pill in young children, according to ABC News.
The treatment, Paxlovid, was authorized in December 2020 by the U.S. Food and Drug Administration for emergency use in patients aged 12 and older who have mild-to-moderate symptoms and are at increased risk of severe illness.
The new trial is planning to enroll 140 children between ages 6 and 17 who will be split into two groups.
One group will weigh between 44 and 88 pounds and the other groups will weigh more than 88 pounds.
The group that weighs more than 88 pounds will be given the dose currently authorized for teens and adults while the group that weighs less will be given a smaller dose.
"Since the beginning of the pandemic, more than 11 million children under the age of 18 in the United States alone have tested positive for COVID-19, representing nearly 18% of reported cases and leading to more than 100,000 hospital admissions," Mikael Dolsten, chief scientific officer and president of worldwide research, development and medical at Pfizer, said in a company statement.
Children under age 6 will not be included in this study, but Pfizer said research is ongoing to determine the best dose for the youngest of children
Pfizer's pill was hailed as a game-changer because it was the first COVID treatment that did not require an infusion, making it more convenient to give to patients.
© Content from this site must be hyperlinked when used.